AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer

Three scientists win Nobel Prize in chemistry for creating new molecular structure

Boehringer bags FDA okay for new pulmonary fibrosis drug

CAMBRIDGE, Mass. - Editas Medicine, Inc., whose stock has surged over 260% in the past six months according to InvestingPro data

China-based companies are responsible for 20% of drugs in development globally, reflecting the powerhouse role the country has embraced in the pharmaceutical industry.